JPH05164758A - Stabilizing method for saccharide in blood sample - Google Patents
Stabilizing method for saccharide in blood sampleInfo
- Publication number
- JPH05164758A JPH05164758A JP33165491A JP33165491A JPH05164758A JP H05164758 A JPH05164758 A JP H05164758A JP 33165491 A JP33165491 A JP 33165491A JP 33165491 A JP33165491 A JP 33165491A JP H05164758 A JPH05164758 A JP H05164758A
- Authority
- JP
- Japan
- Prior art keywords
- blood sample
- blood
- saccharides
- naf
- collected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】この発明は血液中のブドウ糖,
1,5ーアンヒドログルシトール(ポリオール糖類)等の
糖類を測定するに際し採血後のそれらの成分量の変化,
特に細菌等の微生物による変化を防止して正確な測定値
を得るための方法に関するものである。BACKGROUND OF THE INVENTION This invention relates to glucose in blood,
Changes in the amounts of these components after blood sampling when measuring sugars such as 1,5-anhydroglucitol (polyol sugar),
In particular, the present invention relates to a method for preventing changes caused by microorganisms such as bacteria and obtaining accurate measurement values.
【0002】[0002]
【従来の技術】糖尿病等の診断のために血液中のブドー
糖等の糖類の値を測定する場合に試料血液を採血して分
析を行う。その場合に試料をそのまま室温に放置すると
血液中の赤血球等の本来的に血液に含まれている細胞中
の解糖酵素群による解糖反応が進行する。一般に血液の
試料を採血して分析作業をする迄に少なくとも2〜3時
間(病院等の自所分析の場合),場合によっては数十時
間(他所依頼の場合)の時間があり,従って前記解糖反
応を防止する必要があった。2. Description of the Related Art When measuring the value of sugars such as budo sugar in blood for the diagnosis of diabetes and the like, sample blood is collected and analyzed. In that case, if the sample is left as it is at room temperature, the glycolytic reaction by the glycolytic enzyme group in cells originally contained in blood such as red blood cells in blood proceeds. Generally, it takes at least 2-3 hours (in the case of in-house analysis at a hospital, etc.) and, in some cases, several tens of hours (in the case of requesting another place) before the blood sample is collected and analyzed. It was necessary to prevent the sugar reaction.
【0003】更に最近では,例えば川合厚生氏他,
「1.5ーアンヒドログルシトール」,臨床検査 vol.
33, No.8,1989年8月にあるように,糖尿病に対する
マーカーとして1,5アンヒドログルシトールを同時に
測定することが行われるようになった。該成分も時間の
経過と共に減少する。More recently, for example, Kosei Kawai et al.
"1.5-anhydroglucitol", clinical test vol.
33, No. 8, August 1989, simultaneous measurement of 1,5 anhydroglucitol as a marker for diabetes has come to be performed. The component also decreases over time.
【0004】これに対し従来からフッ素化合物やモノヨ
ード酢酸を主体とした解糖阻止剤を添加したりすること
が行われていたがその効果は万全ではなかった。On the other hand, addition of a glycolytic inhibitor mainly containing a fluorine compound or monoiodoacetic acid has been conventionally performed, but the effect was not perfect.
【0005】本発明者らは試料として採取した血液に酸
を加えてpHが5.0〜7.0になるように試料の酸性
度を調整することにより前記の酵素系による解糖反応を
速効的に阻止できることを発見し特願昭60ー1001
61号(特公開61ー258174号)として出願し
た。また同発明は酸性度を調整し,且つNaF(フッ化
ナトリウム)0.1〜0.5mg/ml を血液試料に添加す
ると阻止効果がより長時間持続することも含まれてい
る。The inventors of the present invention accelerate the glycolysis reaction by the enzyme system by adding acid to the blood collected as a sample to adjust the acidity of the sample so that the pH becomes 5.0 to 7.0. It was discovered that it could be blocked, and Japanese Patent Application No. 60-1001
Application was filed as No. 61 (Japanese Patent Publication No. 61-258174). The invention also includes adjusting the acidity and adding 0.1 to 0.5 mg / ml of NaF (sodium fluoride) to the blood sample to have a longer lasting inhibitory effect.
【0006】[0006]
【発明が解決しようとする課題】前記の採取した血液試
料のpHを調整する方法は解糖阻止法として非常に有効
であった。しかし実際には稀にこの方法によっても解糖
が生ずる場合が存在することが分かった。例えば小林芳
夫氏, 「感染性心内膜炎・敗血症」Medical Technology
Vol19, No.10.には敗血症,感染性心内膜炎の患者では
原因不明の低血糖が認められることが指摘されている。
また普通の血糖値の測定においても稀に解糖作用が生じ
て異常に不正確な値を検出する場合があると言う課題が
あった。The method of adjusting the pH of the collected blood sample was very effective as a glycolysis inhibition method. However, in practice, it was found that there are rare cases where glycolysis occurs even by this method. For example, Yoshio Kobayashi, “Infectious Endocarditis / Sepsis” Medical Technology
It is pointed out in Vol. 19, No. 10 that hypoglycemia of unknown cause is observed in patients with sepsis and infective endocarditis.
Further, there is a problem that even in the usual measurement of blood glucose level, a glycolytic action rarely occurs and an abnormally inaccurate value may be detected.
【0007】[0007]
【課題を解決するための手段】このような実情に鑑み本
発明者らは鋭意研究の結果,前記の血液試料中の糖類の
不安定性は血液中に稀に含まれる赤血球,白血球,血小
板等の血液に本来含まれる細胞以外の他の細菌や微生物
の増殖に伴うブドー糖,及び1,5アンヒドログルシト
ール等の糖類の消費によるものであり,従ってこの不安
定性を解消するには本来含まれる血液細胞中の解糖酵素
群やポリオール代謝酵素系の解糖作用をpH調整その他
の方法で阻止するだけでは不十分であり,他の細胞,微
生物の増殖による糖類の消費を阻止することが必要であ
ることを見い出した。In view of the above situation, the present inventors have earnestly studied, and as a result, the instability of saccharides in the above-mentioned blood sample showed that instability of saccharides such as red blood cells, white blood cells, and platelets rarely contained in blood. It is due to the consumption of sugar such as budo sugar and 1,5 anhydroglucitol accompanying the growth of bacteria and microorganisms other than the cells originally contained in blood. Therefore, it is originally included to eliminate this instability. It is not enough to prevent the glycolytic action of glycolytic enzymes in the blood cells and the polyol-metabolizing enzyme system by adjusting the pH and other methods, and it is possible to prevent the consumption of sugars due to the growth of other cells and microorganisms. I found it necessary.
【0008】すなわち本発明は,血液中のブドー糖,
1.5アンヒドログルシトール等の糖分を分析測定する
場合に採取した血液試料に対し各種酸を用いて採取した
血液試料のpHを5.0〜6.8に調整し,さらに弗酸
塩,例えばNaF(フッ化ナトリウム)を血液1ml当た
り3mg以上を添加する糖類安定化方法であり,これによ
り酵素系による解糖作用と共に細菌,微生物の増殖によ
る糖類の消費を阻止して常に正確な分析値を得ることが
できる。この場合に当量換算で同量の他の弗酸塩を用い
てもよい。That is, the present invention relates to budo sugar in blood,
1.5 The pH of the blood sample collected with various acids is adjusted to 5.0 to 6.8 for the blood sample collected for the analysis and measurement of sugars such as anhydroglucitol, , For example, NaF (sodium fluoride) is a saccharide stabilization method in which 3 mg or more is added per 1 ml of blood, which prevents glycolysis by the enzyme system and the consumption of saccharides due to the growth of bacteria and microorganisms, and always provides accurate analysis. You can get the value. In this case, the same amount of other hydrofluoric acid salt may be used in equivalent conversion.
【0009】採取した血液試料は分析作業を行う前に容
器の移し替え,保存等の処理が行われる。空気中には種
々の雑菌,細菌が存在し,又取扱中の人体との接触等に
より容器等が汚染されることがある。これにより汚染さ
れた血液中にはグラム陰性桿菌,グラム陽性球菌等が多
く含まれることが多い。また感染性心内膜炎・敗血症等
の菌血症の患者の場合には血液中にグラム陽性球菌その
他の細菌が含まれていることが認められている。これら
の細菌や微生物が血液中に存在すると試料の保存等の採
血後の処理過程で,温度,環境,運送等の条件にもよる
が,通常状態では細菌,微生物は血液中で容易に増殖し
て,増殖にともなうブトー糖や1.5アンヒドログルシ
トールの消費が生ずるのであり,これが前記課題の生ず
る原因であった。The collected blood sample is subjected to processing such as container transfer and storage before analysis work. Various bacteria and bacteria are present in the air, and containers and the like may be contaminated by contact with the human body during handling. Blood contaminated by this often contains a large amount of Gram-negative bacilli, Gram-positive cocci, and the like. Further, in the case of patients with bacteremia such as infectious endocarditis and sepsis, it has been confirmed that blood contains gram-positive cocci and other bacteria. If these bacteria and microorganisms are present in the blood, they may easily grow in the blood under normal conditions, depending on the conditions such as temperature, environment, and transportation during the process of blood sampling such as sample preservation. As a result, butote sugar and 1.5 anhydroglucitol are consumed during the growth, which is the cause of the above problems.
【0010】弗酸塩,特にNaFは従来から単独もしく
はEDTAやヘパリンと併用して用いられており,その
濃度として血液1ml当たり1〜10mgの範囲で用いられ
ることが多いし,また弗酸塩としてNaFを用いると3
mg/ml以上で溶血が生ずる恐れがあるので普通は1.2
5mg/ml程度を使用している。しかし単に弗酸塩をこの
条件下で添加しても血液中に混入した細菌,微生物の増
殖を阻止することはできない。Hydrofluoric acid salts, especially NaF, have been conventionally used alone or in combination with EDTA and heparin, and the concentration thereof is often in the range of 1 to 10 mg per 1 ml of blood, and as the hydrofluoric acid salt. 3 with NaF
It is usually 1.2 because hemolysis may occur at more than mg / ml.
About 5 mg / ml is used. However, simply adding hydrofluoric acid under these conditions cannot prevent the growth of bacteria and microorganisms mixed in blood.
【0011】[0011]
【作用】本発明のように,採血後の血液試料を酸により
pHを5.0〜6.8に低下(酸性化)させると,特願
昭60ー100161号(特公開61ー258174
号)にあるように,血液細胞中の解糖系諸酵素による解
糖を即時的に阻止することができる。さらにこの条件下
で弗素化合物(例えばNaF)を血液1ml当たり3mg以
上の濃度になるように添加すると,その条件下で初めて
細菌,微生物の増殖が抑制される。また酸性度を低下し
た状態ではNaFが3mg/ml以上の濃度にしても溶血が
生じない。As in the present invention, when the pH of a blood sample after blood collection is lowered (acidified) to 5.0 to 6.8 by acid, Japanese Patent Application No. 60-100161 (Japanese Patent Publication No. 61-258174).
No.), glycolysis by various glycolytic enzymes in blood cells can be immediately blocked. Furthermore, if a fluorine compound (for example, NaF) is added under this condition so as to have a concentration of 3 mg or more per 1 ml of blood, the growth of bacteria and microorganisms will be suppressed only under those conditions. When the acidity is lowered, hemolysis does not occur even if the concentration of NaF is 3 mg / ml or more.
【0012】本発明を実施するには,例えば血液採取試
験管にクエン酸, クエン酸ーナトリウム,EDTAー2
Na,NaFからなる顆粒状の薬剤を予め規定量入れて
おき,該試験管に採取した血液を規定量だけ注入するか
あるいは直接採取して,そのまま保存して普通の手段に
よりブドー糖,1.5アンヒドログルシトールを定量す
ればよい。To carry out the present invention, for example, a blood collection test tube is provided with citric acid, sodium citrate, EDTA-2.
A prescribed amount of a granular drug composed of Na and NaF is put in advance, and a prescribed amount of blood collected in the test tube is infused or directly collected, and stored as it is by a conventional means. 5 Anhydroglucitol may be quantified.
【0013】[0013]
【実施例】血液を採取して(a) pHを5.5に調整した
血液試料(従来法),(b) NaFを4mg/mlを添加した
血液試料(従来法),(c) 試料採取管にクエン酸,クエ
ン酸ナトリウム,EDTAー2Na,NaF を16:
34:23:27の比率で混和して顆粒化した薬剤を1
2mg/ml(血液当たり)入れて混和した試料(本発明
法),の3つの試料を造った。これらの試料にセラチア
菌(グラム陰性桿菌の一種)を105 個/ml(血液当た
り)を投入して,37°Cで放置してブドー糖の濃度を
分析測定して比較したところ図1の通りであった。この
結果から本発明の方法によると血液中の糖類を安定的に
測定することができることが分かる。尚1.5アンヒド
ログルシトールの測定においても同様の結果が得られ
た。[Examples] Blood was collected (a) Blood sample with pH adjusted to 5.5 (conventional method), (b) Blood sample with NaF added at 4 mg / ml (conventional method), (c) Sampling Tubes with citric acid, sodium citrate, EDTA-2Na, NaF 16:
1: 1 of granulated drug mixed in the ratio of 34:23:27
Three samples were prepared by mixing 2 mg / ml (per blood) and mixing (method of the present invention). When 10 5 cells / ml (per blood) of Serratia bacteria (a kind of Gram-negative bacillus) were added to these samples, the samples were allowed to stand at 37 ° C and the concentrations of budo sugars were analyzed and measured for comparison. It was on the street. From these results, it can be seen that the method of the present invention enables stable measurement of sugars in blood. Similar results were obtained in the measurement of 1.5 anhydroglucitol.
【0014】[0014]
【発明の効果】以上に詳しく説明したように,本発明の
方法は血液中のブドー糖,1.5アンヒドログルシトー
ルを測定する際に,採取血液試料に酸,特にクエン酸を
添加して血液のpHを5.0〜6.8に調整すると共に
弗酸塩の添加を併用することによって,血液中の血液細
胞中の解糖酵素群による解糖反応と細菌を始めとする微
生物の容器の汚染や空気中からの混入の場合にそれらの
増殖による糖類,ブドウ糖や1.5アンヒドログルシト
ールの消費(減少)を共に阻止できるものであり,これ
により試料採取後,分析作業まで数十時間が経過,保存
しても正確な分析値を得ることができる。血糖値,1.
5アンヒドログルシトールの検査,特に大量に試料の検
査を行う場合に非常に有効な方法である。As described above in detail, according to the method of the present invention, an acid, particularly citric acid, is added to a collected blood sample when measuring budo sugar and 1.5 anhydroglucitol in blood. The pH of blood is adjusted to 5.0 to 6.8 and the addition of hydrofluoric acid is used in combination, so that the glycolytic reaction by the glycolytic enzyme group in blood cells in blood and the microorganisms such as bacteria It can prevent consumption (reduction) of saccharides, glucose and 1.5 anhydroglucitol due to their growth in the case of container contamination or contamination from the air, which allows sample collection to analysis work. Accurate analysis values can be obtained even after storage for several tens of hours. Blood glucose level, 1.
This is a very effective method for testing 5 anhydroglucitol, especially when testing a large amount of samples.
【図1】 各種の解糖阻止法を行った試料血液にセラチ
ア菌を105 個/ml(血液当たり)を添加して室温に保
持した時のブドー糖値の時間的変化を示すグラフであ
る。図中,(a) pH調整法(従来法),(b) NaFを添
加する方法(従来法),(c) 本発明の方法の場合を示
す。FIG. 1 is a graph showing time-dependent changes in the glucose level of budo sugar when 10 5 cells / ml (per blood) of Serratia bacteria were added to blood samples subjected to various glycolysis inhibition methods and kept at room temperature. .. In the figure, (a) pH adjustment method (conventional method), (b) method of adding NaF (conventional method), (c) case of the method of the present invention are shown.
Claims (5)
シトール等の糖分を分析測定する方法において,採取し
た血液試料に対し各種酸を用いて採取した血液試料のp
Hを5.0〜6.8に調整し,さらに弗酸塩をNaFに
当量換算して血液1ml当たり3mg以上を添加し血液試料
を分析定量することを特徴とする血液試料中の糖類安定
化方法1. A method for analyzing and measuring sugars such as budo sugar and 1.5 anhydroglucitol in blood, wherein p of a blood sample collected by using various acids with respect to the collected blood sample.
Stabilization of saccharides in a blood sample, characterized by adjusting H to 5.0 to 6.8, further adding 3 mg or more per 1 ml of blood by converting the equivalent of hydrofluoric acid into NaF Method
(フッ化ナトリウム)を用いることを特徴とする請求項
1記載の血液試料中の糖類安定化方法2. Citric acid as an acid, NaF as a fluorine salt
(Sodium fluoride) is used, The method for stabilizing saccharides in a blood sample according to claim 1, wherein
ログルシトールもしくは両者を分析測定することを特徴
とする請求項1〜2いずれかに記載の血液試料中の糖類
安定化方法3. A method for stabilizing saccharides in a blood sample according to claim 1, wherein budo sugar, 1.5 anhydroglucitol, or both are analytically measured as saccharides.
トリウム,EDTAー2Na,NaFからなる顆粒状の
薬剤を予め規定量入れ,該試験管に採取した血液を規定
量だけ注入するかあるいは該試験管に直接採取して後,
ブドー糖,1.5アンヒドログルシトールを定量するこ
とを特徴とする請求項1〜3いずれかに記載の血液試料
中の糖類安定化方法4. A blood collecting test tube is preliminarily filled with a specified amount of a granular drug consisting of citric acid, sodium citrate, EDTA-2Na and NaF, and the specified amount of blood collected is injected into the test tube or After collecting directly into a test tube,
The method for stabilizing saccharides in a blood sample according to any one of claims 1 to 3, characterized in that budo sugar and 1.5 anhydroglucitol are quantified.
Aー2NA,NaFを16:34:23:27の比率で
混和して顆粒状とした薬剤を用いることを特徴とする請
求項4記載の血液試料中の糖類安定化方法5. Citric acid, citric acid-sodium, EDT
The method for stabilizing saccharides in a blood sample according to claim 4, wherein a drug which is made into a granule by mixing A-2NA and NaF in a ratio of 16: 34: 23: 27 is used.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3331654A JPH0820452B2 (en) | 1991-12-16 | 1991-12-16 | Method for inhibiting consumption of sugars in blood by microorganisms |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3331654A JPH0820452B2 (en) | 1991-12-16 | 1991-12-16 | Method for inhibiting consumption of sugars in blood by microorganisms |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05164758A true JPH05164758A (en) | 1993-06-29 |
JPH0820452B2 JPH0820452B2 (en) | 1996-03-04 |
Family
ID=18246090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3331654A Expired - Lifetime JPH0820452B2 (en) | 1991-12-16 | 1991-12-16 | Method for inhibiting consumption of sugars in blood by microorganisms |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0820452B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858699A (en) * | 1994-04-05 | 1999-01-12 | Northern General Hospital Nhs Trust | Method to stabilize cell suspensions using aged heavy metal solution and paraformaldehyde |
US6197539B1 (en) * | 1993-07-05 | 2001-03-06 | Northern General Hospital N.H.S. Trust | Method for preparing a stabilized blood cell preparation using aged transition metal ion solution |
JP5425062B2 (en) * | 2009-03-05 | 2014-02-26 | 株式会社ビー・エム・エル | Method for measuring glycoalbumin and the like using a control sample containing D-mannitol |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61258174A (en) * | 1985-05-10 | 1986-11-15 | Kyoto Ikagaku Kenkyusho:Kk | Method for prohibiting glycolysis in blood |
-
1991
- 1991-12-16 JP JP3331654A patent/JPH0820452B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61258174A (en) * | 1985-05-10 | 1986-11-15 | Kyoto Ikagaku Kenkyusho:Kk | Method for prohibiting glycolysis in blood |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197539B1 (en) * | 1993-07-05 | 2001-03-06 | Northern General Hospital N.H.S. Trust | Method for preparing a stabilized blood cell preparation using aged transition metal ion solution |
US6197540B1 (en) | 1993-07-05 | 2001-03-06 | Northern General Hospital N.H.S. Trust | Preparation and stabilization of cells using aged transition metal solutions |
US5858699A (en) * | 1994-04-05 | 1999-01-12 | Northern General Hospital Nhs Trust | Method to stabilize cell suspensions using aged heavy metal solution and paraformaldehyde |
JP5425062B2 (en) * | 2009-03-05 | 2014-02-26 | 株式会社ビー・エム・エル | Method for measuring glycoalbumin and the like using a control sample containing D-mannitol |
Also Published As
Publication number | Publication date |
---|---|
JPH0820452B2 (en) | 1996-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0202543B1 (en) | Method of inhibiting glycolysis in blood samples | |
Seligson et al. | The measurement of ammonia in whole blood, erythrocytes, and plasma | |
Bond et al. | Use of pulmonary hydrogen (H 2) measurements to quantitate carbohydrate absorption: study of partially gastrectomized patients | |
CA1274457A (en) | Glucose reference control for glucose test strips | |
JPS6158780B2 (en) | ||
EP0596218B1 (en) | Formulation for stabilizing enzymatic activity and immuno-reactivity of creatine kinase and creatine kinase isoenzymes | |
JPH05164758A (en) | Stabilizing method for saccharide in blood sample | |
US4921807A (en) | Method and apparatus for maintaining urine specimens | |
JPH01108997A (en) | Method and reagent for particularly determining fructosamine content of serum in blood or specimen derived from blood,and method for removing specimen component causing nonspecific reductive action or/and suspension | |
JPS63500474A (en) | Method for preventing reduction of glucose content in collected blood | |
JP5425062B2 (en) | Method for measuring glycoalbumin and the like using a control sample containing D-mannitol | |
Brown et al. | Fetal hyperinsulinism in rhesus isoimmunization | |
CA1226794A (en) | Stabilized multiparameter control product | |
US5382525A (en) | Method of effecting increased performance of diagnostic enzyme reaction systems using noble gases | |
Davison et al. | Renal reabsorption of glucose | |
JPH06213885A (en) | Method for conserving urine sample while keeping dissolved constituent | |
JP2628340B2 (en) | Method for stabilizing insulin component in blood | |
WO1995022602A1 (en) | Isoenzyme calibrator/control products | |
JPH0155880B2 (en) | ||
JPH10282095A (en) | Method for stabilizing myoglobin in urine specimen and composition being employed therein | |
JP2603576B2 (en) | How to save cells in urine | |
Easley | Glycosylated hemoglobin in dogs: precision, stability, and diagnostic utility | |
Waldstein et al. | Determination of Exogenous Galactose in Blood using" Specially Purified" Glucose Oxidase | |
Reich et al. | Complement preservation in citrated human blood | |
JPH08136539A (en) | Method for measuring stable saccharified hemoglobin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 19950404 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 19961015 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090304 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090304 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100304 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110304 Year of fee payment: 15 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120304 Year of fee payment: 16 |
|
EXPY | Cancellation because of completion of term |